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Introduction
O ne of the goals of National and Sub national Burden of Diseases, injuries and risk factors from 1990-2013 
(NASBOD) is to estimate the burden of cancer at na-
tional and sub national levels;1 the basic information needed to 
meet this goal is to estimate cancer incidence and prevalence in 
age and sex  categories through evaluating quality of cancer regis-
tered data and computing accurate and complete national and sub 
national  cancer incidence and prevalence estimations.
3RSXODWLRQEDVHGFDQFHUUHJLVWULHVDUHWKH¿UVWDQGXQGHQLDEO\
the most important databases that can be used to estimate the inci-
dence rate of cancer, which is the initial step for computing burden 
of malignancies and the most robust basis for health policy mak-
LQJDQGVFLHQWL¿FUHVHDUFK2 It also helps public health professions 
in programming and implementing policies to control burden of 
cancers more effectively.3 Actually, the quality of data collected 
through the cancer registry is based on four inherent character-
istics of cancer registry systems: Comparability, Completeness, 
Validity, and Timeliness of registered data.
&RPSDUDELOLW\LVWKHH[WHQWWRZKLFKFRGLQJDQGFODVVL¿FDWLRQRI
SURFHGXUHVUHFRUGHGLQWKHUHJLVWU\WRJHWKHUZLWKWKHGH¿QLWLRQVRI
VSHFL¿FGDWDLWHPVDUHFRPSDWLEOHZLWKDJUHHGLQWHUQDWLRQDOJXLGH-
lines.4 Completeness is the extent to which all the cases of cancers 
incident in the population are included in the registry database4 
also as an assessment method, is an extremely important at tribute 
of a cancer registry and is used frequently in many countries.5–17 
Maximum completeness in case-detection procedures will certify 
that incidence rates and survival proportions are close to their true 
values.179DOLGLW\LVGH¿QHGDVWKHSURSRUWLRQRIFDVHVZLWKDJLYHQ
characteristic in a dataset that truly have the attribute.4 Timeliness 
or rapid reporting of cancer cases is another priority for cancer reg-
LVWULHV4XLFNDFFHVVWRFDQFHULQIRUPDWLRQLVRIFOHDUEHQH¿WIRU
health providers and researchers; moreover, the early provision of 
data usually enhances the robustness of the registry.4
&DQFHUGDWDUHSRUWLQJLQ,UDQGDWHVEDFNWRZKHQWKH¿UVW
report of cancer frequency data was prepared and published by 
Prof. Abdollah Habibi, an Iranian pathologist working at Can-
cer Institute of Iran. The report was based on data collected from 
pathologic centers. It included cancer data from 1945 – 1956 
with an incidence rate of 28/100,000 in south and 42/100,000 in 
north of Iran.18–19 Although passive cancer data registration has 
been started since around 1999 in the Center for Disease Control 
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/ Ministry of Health and Medical Education, as it did not cover all 
pathology labs and other departments that had related data about 
FDQFHURXVSDWLHQWDOORYHUWKHFRXQWU\WKH¿UVWUHVXOWVRIQDWLRQDO
reports were not accurate for national estimation. For example, 
WKH¿UVWUHSRUWKDGRQO\FRYHUDJH19 Thereafter, pathologic 
based registration continued until the last national reports in 2009 
that claimed coverage of more than 86 %. Nevertheless, these re-
ports are based on data from the majority of pathologic labs, but 
not all of the centers. There are just a few population-based data in 
DOOSDUWVRIWKHFRXQWU\7KHUHDUHDOVRVRPHLQGHSHQGHQWVFLHQWL¿F
departments like research centers that have domestic data about 
cancer cases, which are population based and reported separately.
As there is still only one center, ministry of health, in Iran that 
gathers data on cancer incidence for national reports in the coun-
try; in this study we are going to quantify the quality of cancer 
registered cases within the national annual data in Iran. 
Methods and materials
Overview
This paper, as a national report, aims to evaluate the quality of 
cancer registered data in certain dimensions including: compara-
bility, completeness, validity, and timeliness.
Comparability
As mentioned in the introduction, to evaluate cancer data com-
parability, data should be reviewed in terms of system of clas-
VL¿FDWLRQDQGFRGLQJGH¿QLWLRQRILQFLGHQFHDQGGLVFULPLQDWLRQ
of primary tumor from invasion, metastasis or recurrence of an 
existing one in asymptomatic patients.4
Timeliness
Although there is no international standard guideline for timeli-
ness in cancer registration, since analyzed data are used for the es-
timation of survival rate, and also for epidemiologic studies on the 
burden of diseases to control cancer, several American agencies 
KDYHVHWRXWVSHFL¿FVWDQGDUGVEDVHGRQWKHWLPHRI¿UVWFRQWDFW
WLPHRIWKH¿UVWFRQWDFWUHFRUGHGLQFDQFHUUHJLVWU\DQGWKHSHULRG
RIWLPHEHWZHHQ¿UVWGLDJQRVLVDQGUHSRUWLQJFRPSOHWHUHFRUGLQJ
of the case.4
Completeness
This part of quality assessment is practically conducted in two dif-
ferent ways: qualitative (semi-quantitative) method, which investi-
gates the registry centers and the process of registration over time; 
and quantitative method, which provides parametric evaluations.4
Semi quantitative methods based on four separate strategies pro-
vide numbers, which show the degree of registered data complete-
ness:17 (These methods are based on historic data, though they 
can’t actually quantify the number of missing cases.)
I. Historic data methods include four assumptions: stability of 
LQFLGHQFHUDWHVRYHUWLPHVKDSHRIDJHVSHFL¿FFXUYHVFRPSDUL-
son of incidence rates between different populations, and inci-
dence rates of childhood cancers;
II. Incidence Mortality(IM) ratios: for this section we will need 
not only the cancer incidence rates reported in national annual re-
SRUWVEXWDOVRWKHFDQFHUVSHFL¿FPRUWDOLW\UDWHUHSRUWHGEDVHGRQ
national death registry;
,,,1XPEHURIVRXUFHVQRWL¿FDWLRQVSHUFDVH
,9+LVWRORJLFDOYHUL¿FDWLRQRIGLDJQRVLV0RUSKRORJLFDOO\FDVH
YHUL¿HG09LVWKHSHUFHQWDJHRIREVHUYHGFRPSDUHGWRH[-
pected values.
Quantitative evaluation includes three methods to estimate the 
degree of completeness in the registration: independent case as-
FHUWDLQPHQW FDSWXUH±UHFDSWXUH PHWKRG DQG GHDWK FHUWL¿FDWH
method. We are going to use the last method, which consists of 
WZRSDUWV'&1,0,PHWKRGDQGWKHµÀRZ¶PHWKRG17,QWKH¿UVW
one, the degree of completeness may be estimated as:
Final registrations
Final registrations + d
Where “d” is the number of people who are registered neither 
LQGHDWKQRULQFDQFHUUHJLVWU\WKH¿QDOUHJLVWUDWLRQVFRYHUWKRVH
who are registered in cancer registry or death registry or both of 
them. To calculate this measure, we need other indicators includ-
LQJ WKHSURSRUWLRQRI'&1'HDWK&HUWL¿FDWH1RWL¿FDWLRQ ,0
(Incidence Mortality) ratio and true IM ratio. To measure these 
items, we require the number of people who were registered in 
UHJLVWUDWLRQ V\VWHPV7KHÀRZPHWKRG WKH VHFRQGRQH FRYHUV
FDVHV WKDW GLGQ¶W KDYH GHDWK FHUWL¿FDWHV7KHVH SDWLHQWV DUH GL-
vided into two groups including patients who are alive and still 
unregistered (missing) and the those who have died without being 
registered during life, and remain unregistered because there is 
QRPHQWLRQRIFDQFHURQWKHLUGHDWKFHUWL¿FDWHORVW7KHPDWK-
ematical analysis and method are reported completely somewhere 
else.17,20
)RUWKH¿UVWWZRSDUWVFRPSDUDELOLW\DQGWLPHOLQHVVZHZLOOXVH
the national annual cancer registry reports alone or maybe along 
with other published Iranian sub national reports about childhood 
cancer incidence. However, for the last part (completeness), child-
hood cancer data should be collected from other countries through 
systematic reviews and in some necessary cases, meta-analysis. 
Then systematic review results along with the regional standards 
published in “Cancer Incidence in Five continents (CI5)” will be 
utilized as two comparable sources of childhood cancer incidence 
statistics of Iran to estimate how much it is complete, over- or 
underestimated21–22LQGH¿QHGSHULRGVRIWLPH
Since national cancer registry of Iran claims that cancer registry 
LVSRSXODWLRQEDVHGWKHUHVKRXOGEHVRXUFHQRWL¿FDWLRQGRFXPHQWV
IRU HYHU\ UHFRUGHGFDVHZKLFKZLOOEHXVHG WR IXO¿OO WKHVH WZR
goals (the third and forth parts of the semi quantitative methods).
Organizing working group 
2XUWHDPZRUNFRQVLVWVRI,UDQLDQH[SHUWVLQWKH¿HOGRIFDQFHU
registry and epidemiology, who are familiar with ICD-10 codes 
for cancer. Both groups are professional in systematic review and 
methods of meta-analysis using STATA software. However, we 
may need experts’ views at other stages as well.
'LVHDVHVGH¿QLWLRQ
This paper just focuses on childhood malignancies originating in 
all parts of body. Malignancies topographies and morphologies are 
GH¿QHGDQGFODVVL¿HGDFFRUGLQJWR,QWHUQDWLRQDO&ODVVL¿FDWLRQ'LV-
eases (ICD) version 10. “Childhood” means ages between 0 – 14 
\HDUVROGDQGLWLVFODVVL¿HGLQWRWKUHHDJHJURXSVRI±±
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±³,QFLGHQFH´LVGH¿QHGDVQHZUHJLVWHUHGFDVHVLQDGH¿QHG
period of time; the unit of measurement will be Age Standardized 
Rate (ASR) overall and in age groups as Incidence Rate (IR) or 
$JH6SHFL¿F5DWH%RWKVH[HVDUHLQFOXGHG7DEOH
Data sources
There are two main sources of data: Iranian national published 
data and internationally published data from other countries. Both 
sources address the incidence of childhood cancer. It is worth 
mentioning that the Iranian national data may not be electronical-
ly available on the internet, since they may be in printed formats.
Search strategy
$VIRU WKH¿UVWGDWDVRXUFH1DWLRQDO5HSRUWRI,UDQZHZLOO
use Annual National Report of cancer registry system, which is 
published every year by the Ministry of Health and Medical Edu-
cation (MOH & ME) of Iran. It is based on pathologic data re-
corded from 2000 to the present, that have been collected from all 
pathologic labs all over the country (including those labs that have 
accepted to send data of cancer samples to cancer units in Medical 
Universities), and population based data in some provinces from 
2009. These reports have been used to estimate incidence rates of 
children malignancies in ages 0 – 14 and categorized as 0 – 4, 5 – 
9, 10 – 14 year-olds, by sex, as annual national records.
As for the second data source, we’ll need to estimate the inci-
dence rates of malignancies in ages 0 – 14 in other countries, if 
available. So we should have a search strategy with inclusion and 
exclusion criteria and we should conduct a systematic review us-
ing the electronic databases including: Pub Med, ISI web of sci-
ences, and Scopus. The search terms and strategies are explained 
in details in Table 2.
$V WKH ¿UVW DYDLODEOH SXEOLVKHG 5HSRUW RI ,UDQ GDWHV EDFN WR
2000, our search strategy is limited to the time period between 
January 01, 2000 and December 31, 2014, utilizing alert system 
of all databases.
The major inclusion criteria consist: date, disease, age group, 
gender, measurement indicator, and type of data gathering source 
(Table 3).
Comparability WKHH[WHQWWRZKLFKWKHFRGLQJDQGFODVVL¿FDWLRQSURFHGXUHVWKHGH¿QLWLRQVRIUHFRUGLQJDQGUHSRUWLQJVSHFL¿Fdata items are consistent with international guidelines
Validity the proportion of cases in a dataset with a given characteristic which truly have the attribute
Timeliness rapid reporting of cancer cases
Completeness the extent to which all the incident cancers occurring in the population are included in the registry database
DCN GHDWKFHUWL¿FDWHPHQWLRQHGEXWDOUHDG\UHJLVWHUHGYLDRWKHUVRXUFHV
DCI 'HDWK&HUWL¿FDWHPHQWLRQHGEXWFRXOGEHUHJLVWHUHGYLDRWKHUVRXUFHV
DCO -XVWRQO\GHDWKFHUWL¿FDWHPHQWLRQHGDQGUHJLVWHUHG
ICDO-10 ,QWHUQDWLRQDO&ODVVL¿FDWLRQRI'LVHDVHV)RU2QFRORJ\YHUVRLQ
Incidence Rate 5DWHRIQHZFDVHVLQDGH¿QLWHSRSXODWLRQDQGGH¿QLWHWLPH
Children Individuals aged between 0-14 years
Table 1. 3UDFWLFDO'H¿QLWLRQ2I&DQFHU5HJLVWU\'DWD4XDOLW\(YDOXDWLRQFRPSRQHQWV4XDOLW\(YDOXDWLRQRI1DWLRQDO&DQFHU5HJLVWU\V\VWHP,UDQ
Table 2. 6HDUFK$FWLYLW\,Q6HDUFK(QJLQHV4XDOLW\(YDOXDWLRQRI1DWLRQDO&DQFHU5HJLVWU\V\VWHP,UDQ
Table 3. 3DSHUH[FOXVLRQDQGLQFOXVLRQ&ULWHULD4XDOLW\(YDOXDWLRQRI1DWLRQDO&DQFHU5HJLVWU\V\VWHP,UDQ 
PubMed  $OO0HVK7HUPVZRXOGEHVHDUFKHGLQ³DOO¿HOG´
ISI(Web of Science) All Mesh Terms and Entry terms would be searched in “Topic”
Scopus All Mesh Terms, Entry terms would be searched in “Title, Abstract, Keyword”
· Mesh Terms: Cancer, children, incidence; Entry Terms: Tumor, tumors, neoplasia, neoplasm, cancers, cyst, child, childhood, epidemiology, incidences; 
Emtree: no new one found; All key words mentioned above in Mesh Terms will be combined with “and” and all key words mentioned above in Entry 
Terms will be combined with “OR” in all engines as follow: (((Tumor OR Tumors OR Neoplasia OR Neoplasm OR Cancer OR Cancers OR Cyst)) AND 
(epidemiology OR incidence OR incidences)) AND (Child OR Childhood OR Children)))
Including
Criteria Additional information
Date 1th Jan 2000 to 31th Dec 2014
Disease Every kind of malignancy, cancer, malignant tumor with topography and morphology as well as related codes based on ICD-10
Age group covering 0-14 years in groups 0-4, 5-9, 10-14 years of age
Gender Both male and/or female
Measurement indicator Incidence Rate (IR, ASR), if incidence is estimated by number, population size reference should be requested for mathematical analysis
Type of data gathering source pathologic and/or population sources
Excluding
Date Before 1th Jan 2000 
Age group not covering 0-14 years of age
Measurement indicator Any other than Incidence Rate
Type of data gathering source Not mentioned as pathologic and/or population sources
Study design Any study with sampling biases such as cohort studies without population base data, case-control studies, clinical trial studies, comparing studies like ethnic based, interventional studies
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The general information presented below will be extracted from 
data sources (Table 4):
y Journal characteristics: name, date of publishing, issue, page, 
web address
y Study name, authors’ names, date of the publication, data 
source, scope and coverage of Study, Doi (if exists), contact ad-
dress of corresponding author(s)
y Population properties: population size, sample size
y Country: name of country , city, urban or/rural areas
y Data coverage: national or sub-national
y)UHTXHQF\RIUHSRUWVDQQXDOHYHU\¿YH±\HDUVDQGVRRQ
Exclusion criteria are (Table 3):
y Unknown source of data
y Data from sample groups with special characteristics
y Study design that may create sampling bias such as cohorts 
without population based data, case-control studies, clinical trial 
studies, comparative ethnic based studies
y Measuring indicators other than incidence (e.g. prevalence)
It is worth mentioning that studies written in any language other 
than English will be included if they match the inclusion criteria.
Statistics and analysis
This study uses the semi-quantitative and quantitative methods 
approved by IARC (International Agency for Research on Can-
FHUDQGDOVRIROORZVH[SHULHQFHVLQRWKHUFRXQWULHVLQWKLV¿HOG
to evaluate the quality degree of our national cancer registry data. 
Data will be entered in Excel sheets and will then be analyzed 
XVLQJ6WDWD6WDWD&RUS&ROOHJH6WDWLRQ7;86$VRIWZDUH
Discussion
Although cancer is one of the most important non-communicable 
diseases with high incidence and prevalence in Iran, there is not 
DQ\QDWLRQDO VFLHQWL¿FGRFXPHQWDWLRQ LQ WKLVDUHD$FFRUGLQJO\
we are going to assess and evaluate the reported national cancer 
UHJLVWU\GDWDDVWKH¿UVWVWHSIRUPHDVXULQJDFFXUDWHLQFLGHQFHUDWH
burden, and trend of all cancers in the country from 1990 to 2013 
in collaboration with experts inside and outside of the country.
Most of cancer quality assessment researches, done worldwide, 
have compared national or sub national data to sub national one; 
for example a study in Gambia National Cancer Registry using 
capture-recapture method showed that the estimate of complete-
ness overall 50.3%,18% of clinically reregistered centers and 45 
RI SDWKRORJLFDO UHSRUWV DQG GHDWK FHUWL¿FDWH WKH HVWLPDWH RI
MV% 18.1 in male and 33.1 in female and DCO %  6.6  in male 
compare to 3.6 in female for the period of 2000 – 2009, consider-
ably lower than international standard references.23
As prior studies in Iran, a study has compared completeness of 
reported and estimated data of cancerous patients diagnosed by 
pathology during 2000-2007 and population-based during 2007 
– 2009 in south of Iran that showed 22.68 % to 118.7 % differ-
ences in data coverage quality.24 Another population-based study 
in northwest of Iran using capture-recapture method showed that 
the under-ascertainment rate for all cancers in the Cancer Registry 
Center of Northwestern of Iran has been 16.1 % over a three–
year period, from 2008 to 2010. The completeness has been 48 % 
based on the national report of the Iranian Cancer Registry Center, 
and 6.9 % combining both resources.25
These studies have assessed just one of cancer registered data, 
completeness, and only in limited provinces data, so in this paper 
we are going to evaluate quality of all components of national 
cancer data such as completeness, comparability, validity and 
timeliness and compare national data to international ones.
Determining accurate data measures such as incidence rate is 
highly essential for estimating the burden of diseases, needed for 
disease control programming at national level. All of the available 
data should be checked and ascertained by experts. Even though 
we will not assess the quality of all parts of the registry system 
through all proven methods due to challenges and lack of enough 
time, we have the chance to evaluate the quality involving com-
parability, validity, and timeliness and to evaluate completeness 
through semi qualitative and quantitative methods as the most im-
portant components of evaluation.
Strength of our study is using the most available methods for as-
VHVVLQJWKHTXDOLW\RIFDQFHUUHJLVWU\IRUWKH¿UVWWLPHDPRQJWKH
Iranian population. Moreover, computing cancer incompleteness 
in two ways, quantitative and qualitative, is the other important 
RQH$FWXDOO\¿QDOUHVXOWVSURYLGHXVZLWKDPRUHDFFXUDWHHVWL-
mation of the national cancer incidence in Iran. 
The limitations of this study are as follows. First of all, in our 
General information
Title
Authors’ names(Surname of First)
Corresponding author’s name and emails
publishing Year 
Country
Article address: site , journal, volume, issue, page, doi
6SHFL¿FLQIRUPDWLRQ
Study Type 
<HDUVRIVWXG\VWDUW	¿QLVK
Reference population (per 100000,or 1000000)
Cancer type
Cancer coding based on ICD-10
Measurement unit (IR, ASR)
Number of new cases
Incidence rate per age group and /or sex
Age groups(<1,1–4,0–4,5–9,10–14,0–14)
Sex (male, female, both)
CI (95%) of rate
Table 4. 'DWD([WUDFWLRQ2SWLRQVLQ67$7$VKHHW4XDOLW\(YDOXDWLRQRI1DWLRQDO&DQFHU5HJLVWU\V\VWHP,UDQ
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systematic review there may be limited access to the full texts of 
certain published or unpublished epidemiological studies, as one 
of the main data sources. Furthermore, many data sources cover 
only a number of demographic characteristics such as age or sex 
groups, or only national or sub national populations. Therefore 
we cannot claim that we will be able to estimate the true incidence 
rates ultimately. 
,QFRQFOXVLRQWKHSUHVHQWVWXG\LVWKH¿UVWFRPSUHKHQVLYHV\V-
tematic effort for assessing the quality of cancer registry system 
among Iranian population. Thus, we are going to present a prob-
ably new method to calculate the real nationwide cancer incidence 
using cancer registry data completeness assessment, in order to 
estimate the trends of prevalence and burden of cancerous dis-
eases from 1990 to 2013 at national and sub-national levels, in 
Iran. This study is a sub-component of National and Sub-national 
Burden of Diseases, injuries and risk factors from 1990 to 2013 
(NASBOD).1
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